Sector News

Israel's BrainStorm names Biogen senior executive Kern as COO

March 7, 2017
Life sciences

Israel’s BrainStorm Cell Therapeutics, which is developing an adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), on Monday named Ralph Kern as chief operating officer.

Kern, who has also been named chief medical officer, joins BrainStorm from Biogen, where he was senior vice president and head of worldwide medical. At Biogen he helped define the company’s therapeutic area and scientific strategies for Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy, Parkinson’s, neurodegeneration and hemophilia.

He was previously head of the neuroscience medical unit at Novartis and global medical director of personalized genetic health at Genzyme Corp.

BrainStorm is preparing to conduct a Phase 3 clinical trial for its NurOwn treatment at multiple sites in the United States and Israel. The company has said the advanced trial is expected to begin enrolling patients in the second quarter.

“I am confident that BrainStorm will become the world leader in adult stem cell therapies for neurodegenerative disorders,” Kern said.

By Tova Cohen

Source: Reuters

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach